Covidien Launches Enhanced Trellis Clot-Busting System

Already available in the U.S., Europe and Canada, Covidien’s Trellis Peripheral infusion system has undergone a makeover. The company has announced the launch of its next generation Trellis system which it says continues to be the only pharmacomechanical thrombolysis device that enables focused treatment of blood clots that lead to Post-thrombotic Syndrome (PTS).


PTS develops when a deep vein thrombosis (DVT) interferes with the blood flow returning from the leg back to the heart. It can cause lower leg pain and swelling and can damage the valves in the veins that normally stop blood from flowing backwards down the leg. PTS occurs in almost half of patients within two years after DVT and up to 33 percent of patients with PTS develop ulcers and skin deterioration.

The Trellis system provides a way for physicians to dissolve acute thrombus and intervene on DVT before it advances to PTS. The system is comprised of an over-the-wire catheter with two occlusive balloons to close off the treatment area and block drug release to other areas of the body; an infusion zone to deliver the lytic drug; and an oscillation drive unit that disperses the drug to dissolve the clot. The updated Trellis system features enhanced drug delivery and increased amplitude of the dispersion wire to better distribute the drug throughout the clot. Additionally, the new system features a larger aspiration window than the previous version, which allows for better removal of the drug and the dissolved clot.

Company comments

“Covidien is committed to providing clinicians and patients with advanced technology that is clinically relevant and demonstrates economic value. Our clinical data has demonstrated that the Trellis system’s targeted lytic delivery may reduce the risk of bleeding complications normally associated with systemic thrombolytic infusion,” said Mark A. Turco, M.D., chief medical officer, Vascular Therapies, Covidien. “Furthermore, intervening in patients with DVT may help improve long-term outcomes in a population that can suffer significant complications if left untreated.”

Source: Covidien plc., Business Wire

Share your thoughts

Your email address will not be published. Required fields are marked *